Christopher M Hovens

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2686790/publications.pdf

Version: 2024-02-01

123 papers	13,354 citations	61984 43 h-index	25787 108 g-index
124 all docs	124 docs citations	124 times ranked	22917 citing authors

#	Article	IF	Citations
1	Biomarkers of Response to Neoadjuvant Androgen Deprivation in Localised Prostate Cancer. Cancers, 2022, 14, 166.	3.7	0
2	Identification and isolation of slow-cycling glioma stem cells. Methods in Cell Biology, 2022, , 21-30.	1.1	2
3	The Prostate Cancer Immune Microenvironment, Biomarkers and Therapeutic Intervention. Uro, 2022, 2, 74-92.	0.8	3
4	A phase 1b openâ€label study of sodium selenate as a diseaseâ€modifying treatment for possible behavioral variant frontotemporal dementia. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2022, 8, e12299.	3.7	7
5	Role of cell quiescence in glioblastoma cytotoxic resistance and strategies for therapeutic intervention. , 2021, , 319-334.		0
6	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. European Urology, 2021, 80, 632-640.	1.9	61
7	Ductal variant prostate carcinoma is associated with a significantly shorter metastasis-free survival. European Journal of Cancer, 2021, 148, 440-450.	2.8	13
8	Loss of SNAI2 in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy. JCO Precision Oncology, 2021, 5, 1048-1059.	3.0	9
9	MSH2-deficient prostate tumours have a distinct immune response and clinical outcome compared to MSH2-deficient colorectal or endometrial cancer. Prostate Cancer and Prostatic Diseases, 2021, 24, 1167-1180.	3.9	4
10	Transcriptome sequencing and multi-plex imaging of prostate cancer microenvironment reveals a dominant role for monocytic cells in progression. BMC Cancer, 2021, 21, 846.	2.6	3
11	The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade. BJU International, 2021, , .	2.5	2
12	Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment. Cancer Immunology, Immunotherapy, 2021, 70, 1811-1820.	4.2	11
13	Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial. BMJ Open, 2021, 11, e055019.	1.9	4
14	Sodium selenate as a disease-modifying treatment for mildâ€“moderate Alzheimerâ€™s disease: an open-label extension study. BMJ Neurology Open, 2021, 3, e000223.	1.6	7
15	A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia. BMJ Open, 2020, 10, e040100.	1.9	11
16	Detection of ctDNA in plasma of patients with clinically localised prostate cancer is associated with rapid disease progression. Genome Medicine, 2020, 12, 72.	8.2	35
17	Inferring structural variant cancer cell fraction. Nature Communications, 2020, 11, 730.	12.8	33
18	Prostate cancer cellâ€intrinsic interferon signaling regulates dormancy and metastatic outgrowth in bone. EMBO Reports, 2020, 21, e50162.	4.5	58

#	Article	IF	Citations
19	The Impact of Whole Genome Data on Therapeutic Decision-Making in Metastatic Prostate Cancer: A Retrospective Analysis. Cancers, 2020, 12, 1178.	3.7	10
20	What Is Oligometastatic Prostate Cancer?. European Urology Focus, 2019, 5, 159-161.	3.1	24
21	Prostatic nerve subtypes independently predict biochemical recurrence in prostate cancer. Journal of Clinical Neuroscience, 2019, 63, 213-219.	1.5	8
22	Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease. Neurotherapeutics, 2019, 16, 192-202.	4.4	69
23	Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance. Experimental Cell Research, 2019, 374, 353-364.	2.6	31
24	Preparation of fluorescent in situ hybridisation probes without the need for optimisation of fragmentation. MethodsX, 2019, 6, 22-34.	1.6	0
25	Developments in oligometastatic hormone-sensitive prostate cancer. World Journal of Urology, 2019, 37, 2549-2555.	2.2	5
26	Late biochemical recurrence after radical prostatectomy is associated with a slower rate of progression. BJU International, 2019, 123, 976-984.	2.5	6
27	Androgen deprivation therapy promotes an obesity-like microenvironment in periprostatic fat. Endocrine Connections, 2019, 8, 547-558.	1.9	16
28	Obesity suppresses tumor attributable PSA, affecting risk categorization. Endocrine-Related Cancer, 2018, 25, 561-568.	3.1	5
29	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell, 2018, 173, 400-416.e11.	28.9	2,277
30	A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell, 2018, 173, 386-399.e12.	28.9	228
31	Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Reports, 2018, 23, 282-296.e4.	6.4	333
32	Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context. Cell Reports, 2018, 23, 297-312.e12.	6.4	205
33	Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images. Cell Reports, 2018, 23, 181-193.e7.	6.4	683
34	Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Reports, 2018, 23, 172-180.e3.	6.4	119
35	Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types. Cell Reports, 2018, 23, 213-226.e3.	6.4	83
36	Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Systems, 2018, 6, 271-281.e7.	6.2	605

#	Article	IF	Citations
37	Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. Cell Systems, 2018, 6, 282-300.e2.	6.2	284
38	Periprostatic fat tissue transcriptome reveals a signature diagnostic for high-risk prostate cancer. Endocrine-Related Cancer, 2018, 25, 569-581.	3.1	19
39	lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer. Cancer Cell, 2018, 33, 706-720.e9.	16.8	400
40	Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell, 2018, 33, 676-689.e3.	16.8	750
41	Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients. Cancer Cell, 2018, 34, 211-224.e6.	16.8	623
42	Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin. Journal of Neuro-Oncology, 2017, 131, 321-329.	2.9	17
43	Accelerated kindling epileptogenesis in Tg4510 tau transgenic mice, but not in tau knockout mice. Epilepsia, 2017, 58, e136-e141.	5.1	30
44	Routinely reported â€˜equivocalâ€™ lymphovascular invasion in prostatectomy specimens is associated with adverse outcomes. BJU International, 2017, 119, 567-572.	2.5	15
45	How Subclonal Modeling Is Changing the Metastatic Paradigm. Clinical Cancer Research, 2017, 23, 630-635.	7.0	34
46	Androgen synthesis in prostate cancer: do all roads lead to Rome?. Nature Reviews Urology, 2017, 14, 49-58.	3.8	34
47	Disrupting the Status Quo in Prostate Cancer Diagnosis. European Urology, 2017, 71, 193-194.	1.9	2
48	Mitochondrial genome variation and prostate cancer: a review of the mutational landscape and application to clinical management. Oncotarget, 2017, 8, 71342-71357.	1.8	28
49	A Phase IIa Randomized Control Trial ofÂVELO15 (Sodium Selenate) inÂMild-Moderate Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2016, 54, 223-232.	2.6	53
50	Comparing nodal versus bony metastatic spread using tumour phylogenies. Scientific Reports, 2016, 6, 33918.	3.3	19
51	Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis. Clinical Cancer Research, 2016, 22, 3132-3137.	7.0	28
52	Sodium selenate, a protein phosphatase 2A activator, mitigates hyperphosphorylated tau and improves repeated mild traumatic brain injury outcomes. Neuropharmacology, 2016, 108, 382-393.	4.1	60
53	Sodium selenate retards epileptogenesis in acquired epilepsy models reversing changes in protein phosphatase 2A and hyperphosphorylated tau. Brain, 2016, 139, 1919-1938.	7.6	100
54	A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance. British Journal of Cancer, 2016, 114, 454-462.	6.4	78

#	Article	IF	Citations
55	Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression. Oncotarget, 2016, 7, 31384-31392.	1.8	11
56	Does perineural invasion in a radical prostatectomy specimen predict biochemical recurrence in men with prostate cancer?. Canadian Urological Association Journal, 2015, 9, 252.	0.6	21
57	Sodium selenate reduces hyperphosphorylated tau and improves outcomes after traumatic brain injury. Brain, 2015, 138, 1297-1313.	7.6	131
58	Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer. Nature Communications, 2015, 6, 6605.	12.8	312
59	Repair mechanisms help glioblastoma resist treatment. Journal of Clinical Neuroscience, 2015, 22, 14-20.	1.5	48
60	Evaluation of models predicting insignificant prostate cancer to select men for active surveillance of prostate cancer. Prostate Cancer and Prostatic Diseases, 2015, 18, 137-143.	3.9	11
61	The Molecular Taxonomy of Primary Prostate Cancer. Cell, 2015, 163, 1011-1025.	28.9	2,435
62	Preoperative biomarkers of tumour vascularity are elevated in patients with glioblastoma multiforme. Journal of Clinical Neuroscience, 2015, 22, 1802-1808.	1.5	4
63	Target Acquired: Progress and Promise of Targeted Therapeutics in the Treatment of Prostate Cancer. Current Cancer Drug Targets, 2015, 15, 394-405.	1.6	5
64	Curated MicroRNAs in Urine and Blood Fail to Validate as Predictive Biomarkers for High-Risk Prostate Cancer. PLoS ONE, 2014, 9, e91729.	2.5	43
65	Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the HumanMethylation450 array. BMC Genomics, 2014, 15, 51.	2.8	126
66	Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder. Pathology, 2014, 46, 274-282.	0.6	17
67	Androstenedione Is the Preferred Androgen Source in Hormone Refractory Prostate Cancerâ€"Response. Clinical Cancer Research, 2014, 20, 4972-4973.	7.0	1
68	Percutaneous image-guided biopsy of prostate cancer metastases yields samples suitable for genomics and personalised oncology. Clinical and Experimental Metastasis, 2014, 31, 159-167.	3.3	8
69	Hyperphosphorylated Tau is Implicated in Acquired Epilepsy and Neuropsychiatric Comorbidities. Molecular Neurobiology, 2014, 49, 1532-1539.	4.0	46
70	Gene-based urinary biomarkers for bladder cancer: An unfulfilled promise?. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 48.e9-48.e17.	1.6	38
71	Canonical Androstenedione Reduction Is the Predominant Source of Signaling Androgens in Hormone-Refractory Prostate Cancer. Clinical Cancer Research, 2014, 20, 5547-5557.	7.0	43
72	Expression of the adaptor protein Tks5 in human cancer: Prognostic potential. Oncology Reports, 2014, 32, 989-1002.	2.6	22

#	Article	IF	Citations
73	Loss of APKC expression independently predicts tumor recurrence in superficial bladder cancers. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 649-655.	1.6	11
74	Bladder Cancer Biorepositories in the â€œ-Omicsâ€•Era: Integrating Quality Tissue Specimens with Comprehensive Clinical Annotation. Biopreservation and Biobanking, 2013, 11, 166-172.	1.0	4
75	Glycogen synthase kinase-3Î² (GSK-3Î²) and its dysregulation in glioblastoma multiforme. Journal of Clinical Neuroscience, 2013, 20, 1185-1192.	1.5	36
76	Presence or absence of a positive pathological margin outperforms any other marginâ€•associated variable in predicting clinically relevant biochemical recurrence in <scp>G</scp>leason 7 prostate cancer. BJU International, 2013, 111, 921-927.	2.5	17
77	Targeting Stat3 and Smad7 to restore TGF-Î² cytostatic regulation of tumor cells in vitro and in vivo. Oncogene, 2013, 32, 2433-2441.	5.9	72
78	Reply: On the clinical relevance of circulating endothelial cells and platelets in prostate cancer. British Journal of Cancer, 2013, 108, 1388-1388.	6.4	1
79	Tumor vascularity in prostate cancer: an update on circulating endothelial cells and platelets as noninvasive biomarkers. Biomarkers in Medicine, 2013, 7, 879-891.	1.4	4
80	Error rates in a clinical data repository: lessons from the transition to electronic data transferâ€”a descriptive study. BMJ Open, 2013, 3, e002406.	1.9	40
81	International multicentre study examining selection criteria for active surveillance in men undergoing radical prostatectomy. British Journal of Cancer, 2012, 107, 1467-1473.	6.4	23
82	Levels of a subpopulation of platelets, but not circulating endothelial cells, predict early treatment failure in prostate cancer patients after prostatectomy. British Journal of Cancer, 2012, 107, 1564-1573.	6.4	17
83	Microscopic assessment of fresh prostate tumour specimens yields significantly increased rates of correctly annotated samples for downstream analysis. Pathology, 2012, 44, 204-208.	0.6	12
84	Regulation of glycogen synthase kinase-3 beta (GSK-3Î²) by the Akt pathway in gliomas. Journal of Clinical Neuroscience, 2012, 19, 1558-1563.	1.5	55
85	Targeting hyperphosphorylated tau with sodium selenate suppresses seizures in rodent models. Neurobiology of Disease, 2012, 45, 897-901.	4.4	70
86	Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours. BJU International, 2012, 109, 660-664.	2.5	66
87	The ability of prostateâ€•specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. BJU International, 2012, 110, 36-42.	2.5	61
88	Positive surgical margins are a risk factor for significant biochemical recurrence only in intermediateâ€•risk disease. BJU International, 2012, 110, 821-827.	2.5	28
89	Potential use of circulating endothelial cells as a biomarker of renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 237-243.	1.6	5
90	Prostate tumour volume is an independent predictor of early biochemical recurrence in a high risk radical prostatectomy subgroup. Pathology, 2011, 43, 138-142.	0.6	26

#	Article	IF	Citations
91	Upgrade in Gleason score between prostate biopsies and pathology following radical prostatectomy significantly impacts upon the risk of biochemical recurrence. BJU International, 2011, 108, E202-E210.	2.5	103
92	Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer. British Journal of Cancer, 2010, 103, 462-468.	6.4	48
93	Circulating endothelial cells and progenitors: potential biomarkers of renal cell carcinoma. BJU International, 2010, 106, 1081-1087.	2.5	10
94	Paraneoplastic syndromes in prostate cancer. Nature Reviews Urology, 2010, 7, 681-692.	3.8	46
95	Expression of ErbB-1 and ErbB-2 in meningioma. Journal of Clinical Neuroscience, 2010, 17, 1155-1158.	1.5	8
96	Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimerâ€™s disease model. Journal of Clinical Neuroscience, 2010, 17, 1025-1033.	1.5	134
97	Snail expression is an independent predictor of tumor recurrence in superficial bladder cancers. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 591-596.	1.6	46
98	VEGF Polymorphisms are Associated With an Increasing Risk of Developing Renal Cell Carcinoma. Journal of Urology, 2010, 184, 1273-1278.	0.4	46
99	Tumour angiogenesis: Its mechanism and therapeutic implications in malignant gliomas. Journal of Clinical Neuroscience, 2009, 16, 1119-1130.	1.5	98
100	Aurora kinase B is an independent protective factor in superficial bladder tumours with a dysfunctional G1 checkpoint. BJU International, 2008, 102, 247-252.	2.5	3
101	Circulating endothelial cells as biomarkers of prostate cancer. Nature Reviews Urology, 2008, 5, 445-454.	1.4	22
102	Targeting malignant glioma survival signalling to improve clinical outcomes. Journal of Clinical Neuroscience, 2007, 14, 301-308.	1.5	82
103	Expression of ErbB-1 and 2 in vestibular schwannomas. Journal of Clinical Neuroscience, 2007, 14, 1199-1206.	1.5	15
104	AF6/sâ€afadin is a dual residency protein and localizes to a novel subnuclear compartment. Journal of Cellular Physiology, 2007, 210, 212-223.	4.1	27
105	Spred-2 steady-state levels are regulated by phosphorylation and Cbl-mediated ubiquitination. Biochemical and Biophysical Research Communications, 2006, 351, 1018-1023.	2.1	7
106	Eve-3: A liver enriched suppressor of Ras/MAPK signaling. Journal of Hepatology, 2006, 44, 758-767.	3.7	16
107	Interfering with cell-survival signalling as a treatment strategy for prostate cancer. BJU International, 2006, 97, 1149-1153.	2.5	8
108	Distinct requirements for the Sprouty domain for functional activity of Spred proteins. Biochemical Journal, 2005, 388, 445-454.	3.7	41

#	Article	IF	Citations
109	Genetics of glioblastoma multiforme: mitogenic signaling and cell cycle pathways converge. Journal of Clinical Neuroscience, 2005, 12, 1-5.	1.5	38
110	The tumour suppressor protein NF2/merlin:the puzzle continues. Journal of Clinical Neuroscience, 2001, 8, 4-7.	1.5	23
111	Ryk-deficient mice exhibit craniofacial defects associated with perturbed Eph receptor crosstalk. Nature Genetics, 2000, 25, 414-418.	21.4	157
112	The Junction-associated Protein AF-6 Interacts and Clusters with Specific Eph Receptor Tyrosine Kinases at Specialized Sites of Cellâ€“Cell Contact in the Brain. Journal of Cell Biology, 1999, 144, 361-371.	5.2	187
113	Mutagenesis and selection of PDZ domains that bind new protein targets. Nature Biotechnology, 1999, 17, 170-175.	17.5	84
114	An epitope tagged mammalian/prokaryotic expression vector with positive selection of cloned inserts. Gene, 1997, 197, 337-341.	2.2	9
115	Useful Vectors for the Two-Hybrid System in Mammalian Cells. BioTechniques, 1997, 23, 396-402.	1.8	21
116	Dual translation cassettes which allow prokaryotic and vertebrate protein expression from the same vector. Technical Tips Online, 1997, 2, 91-93.	0.2	0
117	Two versatile eukaryotic expression vectors permitting epitope tagging, radiolabelling and nuclear localisation of expressed proteins. Gene, 1996, 168, 165-167.	2.2	53
118	An In Vitro Assay of Î²-Galactosidase from Yeast. BioTechniques, 1996, 20, 960-962.	1.8	81
119	Localization of two mouse genes encoding the protein tyrosine kinase receptor-related protein RYK. Mammalian Genome, 1995, 6, 255-256.	2.2	5
120	A B-cell coactivator of octamer-binding transcription factors. Nature, 1995, 373, 360-362.	27.8	307
121	RYK, a receptor tyrosine kinase-related molecule with unusual kinase domain motifs.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 11818-11822.	7.1	123
122	Rapid screening of highly complex cDNA libraries using the polymerase chain reaction. Nucleic Acids Research, 1989, 17, 4415-4416.	14.5	6
123	The application of the polymerase chain reaction to cloning members of the protein tyrosine kinase family. Gene, 1989, 85, 67-74.	2.2	86